RapidAI, a global leader in developing Artificial Intelligence and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced $75 million in Series C funding led by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on the enterprise software, data, and technology markets.
The funding aims to drive platform innovation to support more disease states and go-to-market functions to accelerate growth in new regions and product verticals, reports Healthcare IT Today.
UBS Securities served as financial advisor for RapidAI. Read more.
